Apoptosis has often been described as being synonymous with programmed cell death, implying that apoptosis is the program for cell death. We have recently identified an alternative, non-apoptotic program for cell death that we believe has broad implications in the fields of neurodegeneration, neural development, tumor metastasis, cancer chemotherapy, and the evolution of cell death programs. This alternative program, dubbed paraptosis, is a widespread program for cell death that fulfills none of the morphological or biochemical criteria for apoptosis arid is not inhibited by apoptosis inhibitors. In the current submission, we propose to evaluate the """"""""proteogenomics"""""""" of paraptosis: first, we propose to use DNA microarrays to assess gene expression in paraptosis and to compare it to that in apoptosis. Second, we propose to evaluate the proteomics of paraptosis by performing 2-dimensional polyacrylamide gel electrophoresis followed by nanospray sequencing to identify paraptosis-specific proteolytic cleavage and other protein modifications. Finally, we propose to utilize the yeast 2-hybrid system to identify elements of the """"""""paraptosome,"""""""" i.e., the complex that initiates paraptosis and is analogous to the apoptosome. Because apoptosis inhibitors fail to inhibit paraptosis, and because paraptosis appears to occur in some neurodegenerative disease states, we believe that it will be important to characterize paraptosis biochemically and to develop inhibitors of this program.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1 (01))
Program Officer
Sierra, Felipe
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Buck Institute for Age Research
United States
Zip Code
Shay, Jerry W (2017) New insights into melanoma development. Science 357:1358-1359
Spilman, Patricia R; Corset, Veronique; Gorostiza, Olivia et al. (2016) Netrin-1 Interrupts Amyloid-? Amplification, Increases sA?PP? in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis 52:223-42
Rao, Rammohan V; Descamps, Olivier; John, Varghese et al. (2012) Ayurvedic medicinal plants for Alzheimer's disease: a review. Alzheimers Res Ther 4:22
Sultana, Rukhsana; Robinson, RenĂ£ A S; Lange, Miranda Bader et al. (2012) Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alz Antioxid Redox Signal 17:1507-14
Mukherjee, Abhisek; Soto, Claudio (2011) Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress. Curr Opin Cell Biol 23:223-30
Robinson, R A S; Lange, M B; Sultana, R et al. (2011) Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-? peptide of amyloid precursor protein. Neuroscience 177:207-22
Zhang, Junli; Rao, Rammohan V; Spilman, Patricia et al. (2011) Endogenously EGFP-Labeled Mouse Embryonic Stem Cells. Aging Dis 2:18-29
Butterfield, D Allan; Galvan, Veronica; Lange, Miranda Bader et al. (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48:136-44
Sperandio, Sabina; Poksay, Karen S; Schilling, Birgit et al. (2010) Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 111:1401-12
Fombonne, Joanna; Rabizadeh, Shahrooz; Banwait, Surita et al. (2009) Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. Ann Neurol 65:294-303

Showing the most recent 10 out of 60 publications